Medtronic and KARL STORZ Announce Strategic Collaboration to Expand Access to Integrated ENT Surgical Solutions in the U.S.

June 4, 2026 - Medtronic, a global leader in healthcare technology, today announced a strategic collaboration with visualization technology innovator KARL STORZ to expand access to more integrated ENT surgical solutions for patients in the U.S., advancing its vision for a more connected, intelligent approach to sinus care through its AiBLE™ ENT ecosystem.

The collaboration aligns Medtronic's comprehensive surgical solutions for sinus procedures, including the FDA-cleared Stealth AXiS™ ENT surgical system, with KARL STORZ's industry-leading endoscopy instrumentation and visualization systems. Together, the companies will offer coordinated solutions that help streamline evaluation, procurement, and implementation for ENT operating rooms across the U.S.

"This collaboration is about making it easier for our customers to bring the right technologies together in the OR," said Dan Mendelson, Vice President of Global Marketing for Medtronic's Ear, Nose, & Throat business. "By working alongside KARL STORZ, we're building a more connected ENT surgical ecosystem and expanding access to solutions that support high-quality patient care."

Medtronic will also collaborate closely with KARL STORZ to offer joint medical education opportunities, giving surgeons hands-on experience using both technologies together through fellowship courses and learning sessions at industry congresses.

"Our companies have each helped shape the evolution of procedural sinus and endonasal care through decades of innovation and trusted partnership with clinicians," said Chris Smith, Vice President of Sales & Marketing, Upper Endoscopy at KARL STORZ U.S. "Together, we are energized by the opportunity to align our expertise more closely, delivering a more unified, end-to-end solution while maintaining an unwavering focus on the needs of the clinical end user."

The collaboration represents another step in Medtronic's broader commitment to actively build a connected AiBLE™ ENT surgical ecosystem, with the goal of delivering more predictable, efficient, and data-enabled care. This is aligned with KARL STORZ, where providing care across multiple sites is also a strategic priority, designed to support the full continuum of ENT procedures with visualization excellence.

About the Ear, Nose, & Throat Business at Medtronic
Medtronic's Ear, Nose, and Throat (ENT) business is the global market leader in ENT, delivering innovative technologies that impact nearly 3 million patients each year. For more than 25 years, we have partnered with physicians to advance care across the specialty. Our portfolio supports surgical procedures related to chronic rhinosinusitis and head and neck cancers, spanning surgical navigation, tissue health, powered instruments, localized drug delivery, intraoperative nerve monitoring, and parathyroid detection.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission - to alleviate pain, restore health, and extend life - unites a global team of 95,000+ passionate people across more than 150 countries.

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Product availability, indications, and regulatory status vary by country. Healthcare professionals should refer to the applicable product labeling and instructions for use in their market for indications, warnings, precautions, and operating instructions.

Contacts:
Marie Gentile
Public Relations
+1-404-693-6028

Ingrid Goldberg
Investor Relations
+1-763-505-2696